Supplementary Table S1*a*. Measles serostatus according to sociodemographic and clinical data

|  |  |  |
| --- | --- | --- |
|  | Serostatus of measles specific antibodies |  |
|  | negative | equivocal | positive | p-value |
| Age, years; mean (95%CI)n=1932 | 34.8 (32.4-37.2) | 38.8 (36.7-41) | 47.5 (46.2-47.3) | **<0.001** |
| Gender; n (%) female malen=1937 | 46 (3)16 (4) | 67 (4)19 (4) | 1384 (93)405 (92) | 0.83 |
| Country of birth; n (%) Germany  outside of Germanyn=1913 | 35(3)26 (4) | 56 (4)30 (5) | 1213 (93)553 (91) | 0.15 |
| Mode of HIV acquisition; n (%) MSM Non-MSMn=1899 | 33 (3)29 (3) | 49 (5)35 (4) | 914 (92)839 (93) | 0.54 |
| Duration of HIV infection, years; mean (95% CI) n=1934 | 7.93 (6.03-9.84) | 8.29 (6.7-9.9) | 10.2 (9.8-10.6) | **0.007** |
| CDC stage; n (%) A B Cn=1931 | 51 (4)1 (0)9 (3) | 66 (5)3 (2)16 (4) | 1248 (91)200 (98)337 (93) | **0.017** |
| Baseline CD4+ cell count, cells/μl; mean (95% CI)n=1933 | 554 (471-637) | 556 (496-616) | 589 (574-599) | 0.35 |
| Baseline CD4+ cell count, cells/μl; n (%) <200  ≥200n=1933 | 7 (6)54 (3) | 5 (5)81 (4) | 99 (89)1687 (93) | 0.15 |
| Nadir CD4+ cell count, cells/μl;n (%)n=1902 | 255 (204-305) | 251 (208-293) | 225 (216-234) | 0.27 |
| HIV-RNA; n (%) <40 copies/ml ≥40 copies/mln=1932 | 42 (3)19 (5) | 65 (4)21 (6) | 1448 (93)337 (89) | **0.03** |
| ART; n (%) no ART on ARTn=1935 | 7 (4)55 (3) | 10 (6)76 (4) | 158 (90)1629 (93) | 0.56 |

Supplementary Table S1*b*. Mumps serostatus according to sociodemographic and clinical data

|  |  |  |
| --- | --- | --- |
|  | Serostatus of mumps specific antibodies |  |
|  | negative | equivocal | positive | p-value |
| Age, years; mean (95%CI)n=1926 | 44 (42-45) | 45 (43-46) | 48 (47-48) | **<0.001** |
| Gender; n (%) female malen=1930 | 201 (13)51 (12) | 197 (13)60 (14) | 1092 (73)329 (75) | 0.58 |
| Country of birth; n (%) Germany  outside of Germanyn=1906 | 192 (15)57 (9) | 179 (14)76 (13) | 927 (71)475 (78) | **0.002** |
| Mode of HIV acquisition; n (%) MSM Non-MSMn=1892 | 152 (15)94 (10) | 142 (14)110 (12) | 696 (70)698 (77) | **0.001** |
| Duration of HIV infection, years;mean (±SD);n=1927 | 11 (9.8-12) | 10 (9.5-11.4) | 10 (9.5-10.3) | 0.14 |
| CDC stage n (%) A B Cn=1924 | 166 (12)35 (17)49 (13) | 185 (14)25 (12)46 (13) | 1009 (74)142 (70)267 (74) | 0.36 |
| Baseline CD4+ cell count, cells/μl; n (95% CI)n=1926 | 584 (549-618) | 592 (559-626) | 587 (572-601) | 0.9 |
| Baseline CD4+ cell count, cells/μl; n (%) <200  ≥200n=1926 | 14 (13)238 (13) | 17 (15)240 (13) | 79 (72)1338 (74) | 0.8 |
| Nadir CD4+ cell count, cells/μl;n (%)n=1895 | 225 (201-250) | 221 (200-242) | 229 (218-239) | 0.833 |
| HIV-RNA; n (%) <40 copies/ml ≥40 copies/mln=1925 | 202 (13)49 (13) | 212 (14)45 (12) | 1140 (73)277 (75) | 0.7 |
| ART; n (%) no ART on ARTn=1928 | 22 (13)230 (13) | 19 (11)237 (13) | 131 (76)1289 (73) | 0.6 |

Supplementary Table S1*c*. Rubella serostatus according to sociodemographic and clinical data

|  |  |  |
| --- | --- | --- |
|  | Serostatus of rubella specific antibodies |  |
|  | negative | equivocal | positive | p-value |
| Age, years; mean (95%CI)n=1921 | 43.69 (41-45) | 47.8 (44-51) | 46.98 (46-48) | **0.003** |
| Gender; n (%) female malen=1926 | 116 (8)30 (7) | 38 (3)18 (4) | 1333 (90)391 (89)1 | 0.2 |
| Country of birth; n (%) Germany  outside of Germanyn=1903 | 109 (8)36 (6) | 35 (3)20 (3) | 1152 (89)551 (91) | 0.14 |
| Mode of HIV acquisition; n (%) MSM Non-MSMn=1888 | 82 (8)62 (7) | 28 (3)28 (3) | 877 (89)811 (90) | 0.49 |
| Duration of HIV infection, years;mean (±SD); n=1923 | 10.37 (9.03-11.7) | 10.55 (8.4-12.71) | 10.04 (9.67-10.4) | 0.79 |
| CDC stage; n (%) A B Cn=1920 | 96 (7)14 (7)34 (10) | 44 (3)4 (2)8 (2) | 1218 (90)185 (91)317 (88) | 0.39 |
| Baseline CD4+ cell count, cells/μl;n (95% CI)n=1922 | 538 (493-583) | 585 (509-662) | 591 (578-604) | 0.08 |
| Baseline CD4+ cell count, cells/μl;n (%) <200  ≥200n=1922 | 14 (13)132 (7) | 6 (5)50 (3) | 89 (82)1631 (90) | **0.022** |
| Nadir CD4+ cell count, cells/μl;n (%)n=1892 | 214 (184-245) | 174 (134-214) | 231 (221-240) | 0.069 |
| HIV-RNA; n (%) <40 copies/ml ≥40 copies/mln=1921 | 113 (7)33 (9) | 44 (3)12 (3) | 1392 (90)327 (88) | 0.53 |
| ART; n (%) no ART on ARTn=1924 | 13 (7)133 (8) | 3 (2)53 (3) | 157 (91)1565 (89) | 0.63 |

Supplementary Table S1*d*. Varicella-zoster serostatus according to sociodemographic and clinical data

|  |  |  |
| --- | --- | --- |
|  | Serostatus of varicella-zoster specific antibodies |  |
|  | negative | equivocal | positive | p-value |
| Age, years; mean (95%CI)n=1954 | 39.96 (37-42.8) | 45 (38.2-51.8) | 46.71 (46-47) | **<0.001** |
| Gender; n (%) female malen=1959 | 30 (2)16 (3.6) | 10 (1)7 (2) | 1473 (97)423 (95) | **0.026** |
| Country of birth; n (%) Germany  outside of Germanyn=1933 | 25 (2)19 (3) | 13 (1)4 (1) | 1275 (97)597 (96) | 0.2 |
| Mode of HIV acquisition; n (%) MSM Non-MSMn=1921 | 22 (2)24 (3) | 7 (1)8 (1) | 978 (97)882 (96) | 0.74 |
| Duration of HIV infection, years; mean (±SD)n=1956 | 10.54 (8.1-12.98) | 9.88 (5.34-14.43) | 9.82 (9.47-10) | 0.82 |
| CDC stage; n (%) A B Cn=1953 | 37 (3)5 (2)4 (1) | 10 (1)0 (0)7 (2) | 1352 (97)196 (98)342 (97) | **0.04** |
| Baseline CD4+ cell count, cells/μl; n (95% CI)n=1954 | 653.8 (574-734) | 573.8 (418-730) | 579 (566-591) | 0.194 |
| Baseline CD4+ cell count, cells/μl;n (%) <200  ≥200n=1954 | 1 (1)45 (2) | 2 (2)15 (1) | 123 (98)1768 (97) | 0.33 |
| Nadir CD4+ cell count, cells/μl;n (%)n=1925 | 263 (189-336) | 255 (81-429) | 229 (220-237) | 0.45 |
| HIV-RNA; n (%) <40 copies/ml ≥40 copies/mln=1953 | 40 (3)5 (1) | 14 (1)2 (1) | 1493 (96)399 (98) | 0.19 |
| ART; n (%) no ART on ARTn=1957 | 6 (3)40 (2) | 3 (1)14 (1) | 198 (96)1696 (97) | 0.54 |